CLEC-2E Inhibitors
Chemical inhibitors of CLEC-2E target various signaling pathways to inhibit its function. PP2, as a src-family tyrosine kinase inhibitor, can directly prevent the activation of CLEC-2E by blocking the phosphorylation events that are necessary for its signal transduction. In a similar vein, Dasatinib, with its broad-spectrum inhibition, targets multiple kinases and can effectively halt the phosphorylation and subsequent signaling cascade of CLEC-2E. BAY 61-3606 functions by inhibiting spleen tyrosine kinase (Syk), which plays a crucial role in CLEC-2E-mediated signaling pathways. If Syk is inhibited, the downstream signaling that involves CLEC-2E is blocked, leading to an inhibition of its function within the cell.
Furthermore, LY294002 and Wortmannin both act as inhibitors of phosphatidylinositol 3-kinase (PI3K), a key component in many cellular signaling pathways. The inhibition of PI3K leads to a decrease in the phosphorylation and activation of proteins downstream of CLEC-2E. AG490 exerts its effect by inhibiting Janus kinase 2 (JAK2), thus blocking the activation of CLEC-2E in the JAK-STAT signaling pathway. SB203580 and U0126 target the MAPK pathway, with SB203580 focusing on p38 MAP kinase and U0126 on MEK1/2. By inhibiting these kinases, the activation of CLEC-2E through these pathways is prevented. Additionally, SP600125 inhibits c-Jun N-terminal kinase (JNK), which is another pathway that can regulate CLEC-2E activity. BIBF 1120, while known as a triple angiokinase inhibitor, can also prevent kinase activity essential for CLEC-2E's function. Finally, PD173074 and Gefitinib target the FGFR and EGFR tyrosine kinases, respectively. By inhibiting these receptors, the downstream signaling that could involve CLEC-2E is blocked, leading to the inhibition of the protein's activity. Each of these chemical inhibitors acts on different kinases or pathways that are imperative for the full functional activity of CLEC-2E within cellular signaling networks.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a src-family tyrosine kinase inhibitor, which can inhibit the activation of downstream signaling pathways that CLEC-2E might be involved in, leading to a functional inhibition of CLEC-2E's role in signal transduction. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphatidylinositol 3-kinase (PI3K) inhibitor. Since PI3K is involved in a multitude of signaling pathways, its inhibition can prevent the phosphorylation and activation of proteins that act downstream, including CLEC-2E. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor with the ability to inhibit multiple kinases. Its mechanism of action could inhibit the tyrosine kinase-mediated activation of CLEC-2E, leading to a decrease in its signaling activity. | ||||||
Syk Inhibitor IV, BAY 61-3606 HCl | 732983-37-8 | sc-202351 | 2 mg | $327.00 | 25 | |
BAY 61-3606 is a spleen tyrosine kinase (Syk) inhibitor. Since Syk is part of signaling cascades that can include CLEC-2E, its inhibition can block the function of CLEC-2E in these pathways. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $184.00 $321.00 | 2 | |
BIBF 1120 is a triple angiokinase inhibitor, which can inhibit receptor tyrosine kinases. It can prevent the kinase activity that might be required for CLEC-2E signal transduction, leading to its functional inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor. By inhibiting p38 MAPK, which may be upstream of CLEC-2E, it can halt the activation and function of CLEC-2E in response to cellular stimuli. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, and by inhibiting MEK, it can prevent the activation of ERK, which might be necessary for the functional activity of CLEC-2E in signaling pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K. Inhibition of PI3K can reduce the phosphorylation and activation of downstream proteins, potentially including CLEC-2E, leading to its functional inhibition. | ||||||
AG-490 | 133550-30-8 | sc-202046C sc-202046A sc-202046B sc-202046 | 5 mg 50 mg 25 mg 10 mg | $84.00 $329.00 $223.00 $87.00 | 35 | |
AG490 is a Janus kinase 2 (JAK2) inhibitor. Inhibition of JAK2 can block downstream signaling required for the activation of CLEC-2E, thereby inhibiting its function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). By inhibiting JNK, it can prevent the signaling that may involve CLEC-2E, leading to a reduction in CLEC-2E's functional activity. | ||||||